TEXACORT Drug Patent Profile

When do Texacort patents expire, and what generic alternatives are available?

Texacort is a drug marketed by Mission Pharma and is included in two NDAs.

The generic ingredient in TEXACORT is hydrocortisone. There are sixty-seven drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the hydrocortisone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Texacort

A generic version of TEXACORT was approved as hydrocortisone by IMPAX LABS INC on March 30^th, 2007.

Summary for TEXACORT

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	96
Patent Applications:	4,244
Drug Prices:	Drug price information for TEXACORT
DailyMed Link:	TEXACORT at DailyMed

See drug prices for TEXACORT

Pharmacology for TEXACORT

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

US Patents and Regulatory Information for TEXACORT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mission Pharma	TEXACORT	hydrocortisone	SOLUTION;TOPICAL	080425-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Mission Pharma	TEXACORT	hydrocortisone	SOLUTION;TOPICAL	081271-001	Apr 17, 1992		RX	No	Yes

EU/EMA Drug Approvals for TEXACORT

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Takeda Pharmaceuticals International AG Ireland Branch	Plenadren	hydrocortisone	EMEA/H/C/002185Treatment of adrenal insufficiency in adults.	Authorised	no	no	no	2011-11-03
Diurnal Europe B.V.	Alkindi	hydrocortisone	EMEA/H/C/004416Replacement therapy of adrenal insufficiency in infants, children and adolescents (from birth to < 18 years old).	Authorised	no	no	no	2018-02-09
Diurnal Europe B.V.	Efmody	hydrocortisone	EMEA/H/C/005105Treatment of congenital adrenal hyperplasia (CAH) in adolescents aged 12 years and over and adults.	Authorised	no	no	no	2021-05-27

Market Dynamics and Financial Trajectory for TEXACORT

Last updated: February 20, 2026

What is the current market position of TEXACORT?

TEXACORT (budesonide/formoterol) is an inhaled corticosteroid and long-acting beta-agonist combination used primarily to treat asthma and COPD. Its global market share remains limited due to competition from established brands like Symbicort, Advair, and Breo. Industry reports estimate the global inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) market is valued at approximately USD 15 billion in 2022, with projections reaching USD 22 billion by 2028, growing at a compound annual growth rate (CAGR) of 6-8%. TEXACORT's market penetration relies heavily on regional approval status and marketing strategies.

How is the regulatory landscape affecting TEXACORT?

TEXACORT has obtained regulatory approval in select markets, including Europe and Asia, but is not yet approved by the U.S. Food and Drug Administration (FDA). Without FDA approval, entry into the large U.S. asthma/COPD market remains constrained. Regulatory milestones directly impact revenue potential, with approval in key regions unlocking access to markets representing over 40% of global inhaler sales revenue.

What are the key factors influencing commercial deployment?

1. Market penetration: sales growth depends on formulary inclusion and physician adoption. Reimbursement policies influence prescribing behavior.
2. Competitive landscape: dominant brands like Symbicort (AstraZeneca/Boehringer Ingelheim), Advair (GlaxoSmithKline), and Breo (GSK) possess entrenched market positions, making it difficult for new entrants.
3. Pricing strategies: regulatory and market access considerations dictate pricing models, affecting profitability.
4. Partnerships and licensing: collaborations with regional distributors influence distribution channels and sales volume.

What does the financial outlook look like?

Initial revenue projections for TEXACORT indicate a slow rise, contingent on regulatory approvals and market penetration.

Year	Estimated Revenue (USD millions)	Assumptions
2023	25-50	Market entry in Europe and Asia, limited uptake
2024	75-150	Increased regional approvals, early adoption
2025	200-400	Broader acceptance, formulary listing
2026+	500+	Market saturation, expanded patient access

Additional revenue is expected from licensing deals, royalties, and regional distribution agreements.

What are the primary risks and opportunities?

Risks:

• Delay or denial of regulatory approvals affects revenue timeline.
• High competition limits market share growth.
• Pricing pressures may compress margins.
• Dependence on regional partnerships increases operational complexity.

Opportunities:

• Expanding into emerging markets with high COPD and asthma prevalence.
• Advancing formulation improvements or combination therapies.
• Gaining approvals in strategic regions, notably the U.S.
• Collaborating with regional health authorities to expand formulary access.

Conclusion

TEXACORT remains in early commercialization stages in select markets. Its financial trajectory depends largely on regional regulatory approvals, competitive positioning, and strategic partnerships. While initial revenues are modest, long-term growth potential exists if TEXACORT can penetrate large markets and expand indications.

Key Takeaways

• TEXACORT is limited geographically due to regulatory restrictions.
• The global ICS/LABA market is projected to grow at a 6-8% CAGR.
• Revenue estimates range from USD 25 million in 2023 to over USD 500 million in 2026, depending on market access.
• Major risks include regulatory delays and market competition; opportunities lie in emerging markets and regulatory approvals.
• Strategic partnerships and formulary acceptance remain critical for scaling revenues.

FAQs

What markets are most critical for TEXACORT’s growth?

Europe and Asia offer immediate high-growth opportunities due to earlier approval and less entrenched competition. The U.S. remains a primary long-term target once regulatory hurdles are cleared.

How does TEXACORT compare price-wise to competitors?

Pricing strategies are region-dependent; generally, new entrants price slightly below established brands to gain market share initially. Margins may be compressed with high competition.

What factors influence timing of revenue ramp-up?

Regulatory approvals, formulary inclusions, physician adoption, and regional marketing efforts determine revenue growth trajectory.

Can TEXACORT benefit from pipeline developments?

Yes. Pipeline innovations, including extended-release formulations or combination therapies, can improve market penetration and patient adherence.

What is the likelihood of TEXACORT securing FDA approval?

Given the competitive landscape, the likelihood depends on clinical trial data alignment with FDA requirements and strategic regulatory submissions. No specific timeline is available at this stage.

---

References

1. MarketResearch.com. (2022). Global inhaler market analysis.
2. IQVIA. (2022). Asthma and COPD therapeutics market report.
3. FDA. (2023). Regulatory guidelines for inhaled therapies.
4. Pharma Intelligence. (2023). Regional approvals and market access strategies.
5. Deloitte. (2022). Pharmaceutical industry outlook and growth forecasts.